Ind-Swift Laboratories Limited INDSWFTLAB.NS · Stock Open Ind-Swift Laboratories Limited in new tab
Ind-Swift Laboratories Limited Analysis (INDSWFTLAB.NS)
Is Ind-Swift Laboratories Limited a good investment? Ind-Swift Laboratories Limited (INDSWFTLAB.NS) is currently trading at 141.96 INR.
In terms of valuation, the stock trades at a P/E ratio of 4.12. This relatively low multiple may signal that Ind-Swift Laboratories Limited is undervalued compared to historical market norms.
Earnings Schedule: Ind-Swift Laboratories Limited is expected to release its next earnings report on May 28, 2026.
Investor FAQ
Does Ind-Swift Laboratories Limited pay a dividend?
No, it does not currently pay a dividend.
What asset class is Ind-Swift Laboratories Limited?
Ind-Swift Laboratories Limited is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be May 28, 2026. The company currently has a trailing EPS of 34.49.
Company Profile
Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson's disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, alcohol abstinence, antineoplastic, ADHD symptoms, anticancer, hypercholesterolemia, antimuscarinic, antimigraine, and thrombocytopenia. It also provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, atorvastatin calcium, azithromycin dihydrate, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, clopidogrel hydrochloride, dapoxetine hydrochloride, donepezil hydrochloride, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nateglinide, nitazoxanide, nitrosamine, pazopanib hydrochloride, quetiapine hemifumarate, raltegravir potassium, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide, as well as contract research and manufacturing services. The company exports its products. Ind-Swift Laboratories Limited was incorporated in 1995 and is based in Manimajra, India.
| Year | Total Dividends |
|---|---|
| ▸2011 |
1.00 INR
|
| Oct. 26, 2011 | 1.0000 |
| ▸2010 |
1.00 INR
|
| Oct. 22, 2010 | 1.0000 |
| ▸2009 |
1.00 INR
|
| Oct. 24, 2009 | 1.0000 |
| ▸2008 |
1.00 INR
|
| Nov. 1, 2008 | 1.0000 |
| ▸2007 |
1.00 INR
|
| Nov. 1, 2007 | 1.0000 |
| ▸2006 |
1.50 INR
|
| Nov. 1, 2006 | 1.5000 |
| ▸2005 |
1.50 INR
|
| Oct. 11, 2005 | 1.5000 |
| ▸2004 |
1.00 INR
|
| Oct. 10, 2004 | 1.0000 |
Community Discussion